Search Results - clinical+and+disease+specializations+%3e+oncology

359 Results

Sort By:

Targeted Nano-Delivery of Aurora Kinase Inhibitors for Cancer Therapy

Value Proposition· Kinase inhibition is a highly effective, targeted therapy that is standard of care for many cancers.· Aurora kinase inhibition is a promising class of these therapeutics demonstrated to successfully inhibit tumor growth and promote patient survival in various cancer indications. However, current oral administration requires...

Published: 7/24/2026 | Inventor(s): Sudath Hapuarachchige

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Whole Genome Doubling as a Cancer Prognostic Marker

Value PropositionBroad Applicability: The technology effectively detects multiple different cancer types, including glioblastoma, melanoma, and adenocarcinoma. Simple Methodology: Not reliant on expensive instruments or technology. Most diagnostic labs already possess all the required materials and instruments. Earlier Detection: The technology can...

Published: 7/24/2026 | Inventor(s): Sergi Regot, Adler Guerrero Zuniga

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools

Targeted T-VEC immunotherapy for cutaneous neurofibromas

Value Proposition· Tumor-selective oncolysis: T‑VEC is an engineered oncolytic HSV‑1 that preferentially replicates in and lyses tumor cells, providing direct cytolytic reduction of cutaneous neurofibromas in preclinical models· Local, anti-tumor immune activation: preclinical evidence that tumor cell lysis and local GM-CSF expression promotes...

Published: 7/24/2026 | Inventor(s): Renyuan Bai, Verena Staedtke, Jaishri Blakeley, Carlos Romo

Keywords(s):

Category(s): Clinical and Disease Specializations > Genetic Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology

MRGPRX4 Targeted Therapeutics and Research Tools for Melanoma Diagnosis, Modeling, and Treatment

Unmet NeedMelanoma incidence continues to rise sharply, and current therapies remain inadequate for many patient populations, especially those lacking drug‑targetable mutations such as BRAF. A major limitation in melanoma research and drug discovery is the absence of models and targets that reflect the biology of non‑BRAF‑driven melanoma. Recent findings...

Published: 7/24/2026 | Inventor(s): Xinzhong Dong, Naina Gour

Keywords(s):

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Dermatology

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors

Unmet NeedCancer is the second leading cause of death in the United States, with an estimated 1.8 million cases having been diagnosed and 606,520 people having succumbed to the disease in 2020. The most common cancer diagnosis overall and for women is breast cancer, and the most common cancer diagnosis for men is prostate cancer. Although the 5-year...

Published: 7/24/2026 | Inventor(s): Stavroula Sofou, Alaina Howe

Keywords(s): Breast Cancer, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology

Novel HPV Vaccine

Value Proposition: • A broadly protective vaccine against HPV. • Can be delivered without needles. • Can be chemically synthesized at low cost. Technical Details: Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the United States. Infection by over 15 different oncogenic HPV genotypes is a cause of...

Published: 7/23/2026 | Inventor(s): Hannah Alphs-Jackson, Ratish Gambhira, Richard Roden

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 7/23/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

PSMA-targeting nanoparticle for prostate cancer therapy

Value Proposition:· Engineered nanoparticle system with potent urea-based PSMA inhibitor· Drug loaded nanoparticle· Specific and selective tumor cytotoxicity Unmet NeedProstate cancer affects millions of men globally and is a leading cause of cancer death in men. The management and treatment options for prostate cancer vary based...

Published: 7/23/2026 | Inventor(s): Martin Pomper, Ronnie Mease, Sachin Chandran, Sangeeta Ray, Samuel Denmeade

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Systemic cAMP Modulation as an Adjuvant Chemotherapy for Immunotherapy

Value PropositionAdjuvant to support the widespread use of immunotherapy in cancer.May improve the responses to checkpoint inhibitors (Keytruda) or CAR T cell activity.Diverse applications as a supplement to various precision cancer therapies.Repurposes a commercially available chemical compound for cancer treatment.Scalable synthesis, given the existing...

Published: 7/24/2026 | Inventor(s): Christopher Jackson, Landon Hansen, Eli Yazigi, Henry Brem

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology

RASAL1 and PTEN Co-Alterations Predict Cancer Aggressiveness

Value Proposition· Improved Prognostic Accuracy: Dual detection of RASAL1 and PTEN alterations enables highly accurate identification of aggressive cancers and risk stratification. These biomarkers provide greater precision in identifying aggressive cancers compared to established markers, enabling better patient management. · Pan-Cancer...

Published: 7/24/2026 | Inventor(s): Michael Xing, Xiaopei Shen, Jie Tan

Keywords(s):

Category(s): Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Companion Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Precision Medicine Tools, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > Prognostics Biomarkers, Clinical and Disease Specializations > Oncology

1 2 3 4 5 6 7 8 9 10 ...